DVA stock forecast: what analysts expect
Wall Street analysts covering DaVita Inc. currently rate the stock a Buy on average, with a mean 12-month price target of $218.43 — +20.3% versus the last price of $181.50. Targets reflect analyst opinion, not a guarantee.
DVA historical returns
Based on monthly dividend-adjusted prices. See the full breakdown on what if you had invested in DVA.
DVA annual returns by year
Congress trading in DVA
2 members of Congress have disclosed trading DVA — 2 purchases and 2 sales worth an estimated $32,000. Most recent disclosure: Sep 25, 2025.
Insider activity in DVA
DVA's own executives and directors have made 0 open-market purchases ($0) and 6 sales ($57.2M) in the last 90 days, per SEC Form 4 filings. Most recent: Jul 31, 2026.
| Jul 31, 2026 | Berkshire Hathaway Inc | 10% owner | Sell | $36.5M |
| Jun 16, 2026 | Rodriguez Javier | Chief Executive Officer | Sell | $8.2M |
| Jun 15, 2026 | Waters Kathleen Alyce | Chief Legal & Pub. Affairs Off | Sell | $1.9M |
| Jun 15, 2026 | Waters Kathleen Alyce | Chief Legal & Pub. Affairs Off | Sell | $1.4M |
| Jun 15, 2026 | Rodriguez Javier | Chief Executive Officer | Sell | $6.3M |
About DaVita Inc.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
DVA Key Statistics
DVA in plain English
- P/E ratio (15.1) — how many dollars you pay for each $1 of DVA's yearly profit. That's a fairly normal range.
- ROE (88.48%) — how efficiently the company turns shareholders' money into profit. Above ~20% is considered strong.
- Profit margin (6.05%) — of every $1 in sales, this is what's left as profit after all costs.
- Dividend — DVA doesn't pay a meaningful dividend; the return here comes from the share price, not cash payouts.
DVA stock: frequently asked questions
What is DaVita Inc.'s stock price today?
DaVita Inc. (DVA) last traded at $181.50 on the NYSE. Over the past 52 weeks the stock has traded between $101.00 and $247.49.
Is DVA stock a buy or a sell?
Wall Street analysts' consensus rating on DVA is "Buy", with an average 12-month price target of $218.43 — about +20.3% versus the current price of $181.50. Analyst targets are opinions, not guarantees; always do your own research.
How much would $1,000 invested in DVA 10 years ago be worth today?
A $1,000 investment in DaVita Inc. made 10 years ago would be worth about $2,808 today (dividends reinvested) — a total return of 181%, or 10.9% per year.
Does DVA pay a dividend?
No — DaVita Inc. does not currently pay a meaningful dividend. Returns for shareholders come from changes in the share price.
What is DVA's P/E ratio?
DVA trades at a trailing price-to-earnings ratio of 15.1, and 10.7 times expected forward earnings. The P/E ratio tells you how many dollars investors pay for each $1 of the company's annual profit.
Do members of Congress trade DVA stock?
Yes — 2 members of Congress have disclosed trades in DVA under the STOCK Act, totaling 2 purchases and 2 sales worth an estimated $32,000.
What is DaVita Inc.'s ticker symbol?
DaVita Inc. trades under the ticker symbol DVA on the NYSE.
Compare DVA with peers
Data last refreshed from public sources. Figures may be delayed. Not investment advice.